A citation-based method for searching scientific literature

Claire A Lawson, Samuel Seidu, Francesco Zaccardi, Gerry McCann, Umesh T Kadam, Melanie J Davies, Carolyn Sp Lam, Hiddo L Heerspink, Kamlesh Khunti. EClinicalMedicine 2021
Times Cited: 7







List of co-cited articles
35 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
381
57

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Rajiv Agarwal, Peter Kolkhof, George Bakris, Johann Bauersachs, Hermann Haller, Takashi Wada, Faiez Zannad. Eur Heart J 2021
74
57

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Patrick Schloemer,[...]. N Engl J Med 2021
111
57

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
947
42

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
42

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
516
42

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
42

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Gerasimos Filippatos, Stefan D Anker, Michael Böhm, Mihai Gheorghiade, Lars Køber, Henry Krum, Aldo P Maggioni, Piotr Ponikowski, Adriaan A Voors, Faiez Zannad,[...]. Eur Heart J 2016
170
42

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Bertram Pitt, Lars Kober, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So-Young Kim, Faiez Zannad. Eur Heart J 2013
283
42

Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study.
Bochra Zareini, Paul Blanche, Maria D'Souza, Mariam Elmegaard Malik, Caroline Holm Nørgaard, Christian Selmer, Gunnar Gislason, Søren Lund Kristensen, Lars Køber, Christian Torp-Pedersen,[...]. Circ Cardiovasc Qual Outcomes 2020
9
42

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
208
42

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Luis M Ruilope, Rajiv Agarwal, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Christina Nowack, Peter Kolkhof, Amer Joseph, Nicole Mentenich, Bertram Pitt. Am J Nephrol 2019
80
42

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
Kåre I Birkeland, Johan Bodegard, Jan W Eriksson, Anna Norhammar, Hermann Haller, Gerard C M Linssen, Amitava Banerjee, Marcus Thuresson, Suguru Okami, Elena Garal-Pantaler,[...]. Diabetes Obes Metab 2020
42
42

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
42

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.
Caroline S Fox, Kunihiro Matsushita, Mark Woodward, Henk J G Bilo, John Chalmers, Hiddo J Lambers Heerspink, Brian J Lee, Robert M Perkins, Peter Rossing, Toshimi Sairenchi,[...]. Lancet 2012
651
28

Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.
Josef Coresh, Tanvir Chowdhury Turin, Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Lawrence J Appel, Hisatomi Arima, Steven J Chadban, Massimo Cirillo, Ognjenka Djurdjev,[...]. JAMA 2014
584
28


Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
Peter Kolkhof, Elke Hartmann, Alexius Freyberger, Mira Pavkovic, Ilka Mathar, Peter Sandner, Karoline Droebner, Amer Joseph, Jörg Hüser, Frank Eitner. Am J Nephrol 2021
24
28

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Rajiv Agarwal, Stefan D Anker, George Bakris, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis Ruilope, Martin Gebel, Peter Kolkhof, Christina Nowack,[...]. Nephrol Dial Transplant 2022
18
28

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
28

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
28

Universal Definition and Classification of Heart Failure.
Biykem Bozkurt, Andrew Coats, Hiroyuki Tsutsui. J Card Fail 2021
43
28

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
449
28

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
28

Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, Urszula Masiukiewicz, Richard Pratley, Sam Dagogo-Jack, Robert Frederich, Bernard Charbonnel, James Mancuso, Weichung J Shih,[...]. Circulation 2020
80
28

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
Petar M Seferović, Mark C Petrie, Gerasimos S Filippatos, Stefan D Anker, Giuseppe Rosano, Johann Bauersachs, Walter J Paulus, Michel Komajda, Francesco Cosentino, Rudolf A de Boer,[...]. Eur J Heart Fail 2018
259
28

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
440
28

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
28

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
28

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
28

Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Marc A Pfeffer, Brian Claggett, Susan F Assmann, Robin Boineau, Inder S Anand, Nadine Clausell, Akshay S Desai, Rafael Diaz, Jerome L Fleg, Ivan Gordeev,[...]. Circulation 2015
531
28

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.
Joachim Jankowski, Jürgen Floege, Danilo Fliser, Michael Böhm, Nikolaus Marx. Circulation 2021
109
28

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Mark H Drazner, Gregg C Fonarow, Stephen A Geraci, Tamara Horwich, James L Januzzi,[...]. Circulation 2013
28

Spironolactone for heart failure with preserved ejection fraction.
Bertram Pitt, Marc A Pfeffer, Susan F Assmann, Robin Boineau, Inder S Anand, Brian Claggett, Nadine Clausell, Akshay S Desai, Rafael Diaz, Jerome L Fleg,[...]. N Engl J Med 2014
28


High-normal albuminuria and risk of heart failure in the community.
Saul Blecker, Kunihiro Matsushita, Anna Köttgen, Laura R Loehr, Alain G Bertoni, L Ebony Boulware, Josef Coresh. Am J Kidney Dis 2011
74
14

Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.
Suetonia C Palmer, Dimitris Mavridis, Eliano Navarese, Jonathan C Craig, Marcello Tonelli, Georgia Salanti, Natasha Wiebe, Marinella Ruospo, David C Wheeler, Giovanni F M Strippoli. Lancet 2015
245
14

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
David C Wheeler, Bergur V Stefánsson, Niels Jongs, Glenn M Chertow, Tom Greene, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, Robert D Toto,[...]. Lancet Diabetes Endocrinol 2021
101
14

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Jonatan Barrera-Chimal, Sophie Girerd, Frederic Jaisser. Kidney Int 2019
81
14

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph,[...]. Circulation 2021
80
14

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.
Ron T Gansevoort, Ricardo Correa-Rotter, Brenda R Hemmelgarn, Tazeen H Jafar, Hiddo J Lambers Heerspink, Johannes F Mann, Kunihiro Matsushita, Chi Pang Wen. Lancet 2013
14


Mineralocorticoids in the heart and vasculature: new insights for old hormones.
Achim Lother, Martin Moser, Christoph Bode, Ross D Feldman, Lutz Hein. Annu Rev Pharmacol Toxicol 2015
33
14

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
328
14

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
253
14

Kidney Function and Outcomes in Patients Hospitalized With Heart Failure.
Ravi B Patel, Gregg C Fonarow, Stephen J Greene, Shuaiqi Zhang, Brooke Alhanti, Adam D DeVore, Javed Butler, Paul A Heidenreich, Joanna C Huang, Michelle M Kittleson,[...]. J Am Coll Cardiol 2021
22
14

Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study.
Anna Kottgen, Stuart D Russell, Laura R Loehr, Ciprian M Crainiceanu, Wayne D Rosamond, Patricia P Chang, Lloyd E Chambless, Josef Coresh. J Am Soc Nephrol 2007
243
14

Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
Alberto Ortiz, Charles J Ferro, Olga Balafa, Michel Burnier, Robert Ekart, Jean-Michel Halimi, Reinhold Kreutz, Patrick B Mark, Alexandre Persu, Patrick Rossignol,[...]. Nephrol Dial Transplant 2021
11
14


High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure: Results From the BiomarCaRE Consortium.
Isabell Yan, Christin S Börschel, Johannes T Neumann, Ngoc A Sprünker, Nataliya Makarova, Jukka Kontto, Kari Kuulasmaa, Veikko Salomaa, Christina Magnussen, Licia Iacoviello,[...]. JACC Heart Fail 2020
15
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.